Robert Peterson was named Chief Executive Officer of biote Corp., effective June 8, 2026. As of November 6, 2026, biote Corp. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from June 2, 2026 to June 17, 2026, naming 4 appointments (Form 8-K, June 2, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like biote Corp? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
biote Corp. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-06-02 to 2026-06-17. They name 2 people. Every row below is cited to the filing it comes from, and this page adds each new change as biote Corp. files it.
Also on the record for biote Corp.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| September 18, 2026 | Stake report, Schedule 13G/A, by AGARWAL AMIT MOHAN | 8.4% of the class | 5%+ stakes | Source |
| September 1, 2026 | Stake report, Schedule 13G/A, by AGARWAL AMIT MOHAN | 7.61% of the class | 5%+ stakes | Source |
| August 28, 2026 | Stake report, Schedule 13G, by AGARWAL AMIT MOHAN | 5.92% of the class | 5%+ stakes | Source |
| July 27, 2026 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 1.2% of the class | 5%+ stakes | Source |
| May 13, 2026 | Stake report, Schedule 13G/A, by Bandera Partners LLC | 6.4% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs biote Corp. now and the warning signs.
Free to see. No signup.
Keep reading
More on biote Corp. and the records around it.
biote Corp. elsewhere on the record
Companies that share a holder
- Bandera Partners LLC also filed stake reports on 4 other companies: DYADIC INTERNATIONAL INC (Aug 2025), RED ROBIN GOURMET BURGERS INC (Aug 2025)
- BlackRock, Inc. also filed stake reports on 1596 other companies: AvePoint, Inc. (Nov 2026), BIOMARIN PHARMACEUTICAL INC (Nov 2026), MSG RANGERS CORP (Nov 2026)
Watch biote Corp.
Get an email when biote Corp. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on biote Corp.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on biote Corp.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on biote Corp. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
7 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-06-17 | Reported | not named in the filing | 8-K/A, 2026-06-17 | ||
| 2026-06-02 | In | Chief Executive Officer | 2026-06-08 | 8-K, 2026-06-02 | |
| 2026-06-02 | In | 8-K, 2026-06-02 | |||
| 2026-06-02 | In | Director | 8-K, 2026-06-02 | ||
| 2026-06-02 | In | Executive Chairman | 2026-06-08 | 8-K, 2026-06-02 |
Who leads biote Corp., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Executive Chairman: Marc Beer, appointed, effective 2026-06-08 (filed 2026-06-02).
- Chief Executive Officer: Robert Peterson, appointed, effective 2026-06-08 (filed 2026-06-02).
- Director: Robert Peterson, appointed (filed 2026-06-02).
New leaders reset buying decisions — get the Full Report on biote Corp.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Executive Officer at biote Corp., with the record behind each one.
Find candidates like Chief Executive Officer at biote Corp.Every change, in the filing's words
Reported
Entry into Amended and Restated Employment Agreement with the Interim Chief Executive Officer On June 12, 2026, in connection with his appointment as Interim Chief Executive Officer, Mr. Peterson and BioTE entered into an amended and restated employment agreement (the "Amended and Restated Employment Agreement").
- Under the Amended and Restated Employment Agreement, Mr. Peterson will receive an annual base salary of $658,800, and he is eligible to earn annual incentive compensation of up to 72.5% of his then-current annualized base salary.
- Mr. Peterson will also be granted a stock option award to purchase a number of shares of the Company's common stock equal to 0.56% of the Company's outstanding shares, calculated as of June 8, 2026, and an additional stock option to purchase the same number of shares upon Mr. Peterson's appointment, if any, as BioTE's non-interim Chief Executive Officer.
- Additionally, Mr. Peterson is entitled to receive reimbursement for certain business expenses in accordance with BioTE's standard expense reimbursement policy.
- If Mr. Peterson's employment is terminated by BioTE without cause or he resigns for certain good reasons, and subject to his execution of an effective release of claims against BioTE and the Company, BioTE will continue to pay Mr. Peterson's base salary for the 12 month period following such termination and shall also pay or reimburse health insurance premiums for Mr. Peterson and any eligible dependents under COBRA (or analogous state law) for up to 12 months following such termination without cause or resignation for good reason.
Appointed: Robert Peterson, Chief Executive Officer, effective 2026-06-08
Appointment of Robert Peterson as Interim Chief Executive Officer and Director Concurrently, the Board appointed Robert Peterson, current Chief Financial Officer and Chief Business Officer of BioTE, as Interim Chief Executive Officer of BioTE to fill the vacancy created by Mr. Christensen's resignation, and as a director of the Board, each effective June 8, 2026 (the "Effective Date").
Appointed: Robert Peterson
On the Effective Date, Mr. Peterson will become BioTE's principal executive officer in addition to continuing in his role as principal financial officer.
Appointed: Robert Peterson, Director
Beginning on the Effective Date, Mr. Peterson will serve as a Class I director until the Company's 2029 Annual Meeting of Stockholders, and until such time as his successor is duly elected and qualified, or until his earlier death, resignation or removal.
Appointed: Marc Beer, Executive Chairman, effective 2026-06-08
On June 1, 2026, the Board appointed Marc Beer as Executive Chairman of the Board, effective June 8, 2026.
- Resignation of Bret Christensen as Chief Executive Officer On May 27, 2026, the Board of Directors (the "Board") of biote Corp. (the "Company") accepted the resignation of Bret Christensen, the Company's Chief Executive Officer, from his position as Chief Executive Officer of BioTE Medical, LLC ("BioTE"), effective as of June 8, 2026.
- Such resignation did not result from any disagreement with BioTE or the Company on any matter relating to BioTE's or the Company's operations, policies or practices.
- In connection with his resignation and departure from BioTE, Mr. Christensen and BioTE entered into a separation agreement, dated June 2, 2026 (the "Separation Agreement"), which provides for the terms of Mr. Christensen's resignation from employment.
- Under the terms of the Separation Agreement, Mr. Christensen will have three months following his separation date to exercise any vested options granted to him by the Company, and he will serve on the Board as a Class III director until the Company's 2028 Annual Meeting of Stockholders and until such time as his successor is duly elected and qualified, or until his earlier death, resignation or removal.
Tools for this story
Each opens in a new tab, filled in for biote Corp.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.